Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-25 @ 1:40 AM
NCT ID:
NCT04433494
Brief Summary:
The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are:
* TY-302
* Tamoxifen
Detailed Description:
This is an open-label, single-arm, phase I trial. The purpose of this study is to :
* Test a safe and tolerable dose of TY-302 single and the combination with Tamoxifen
* Determine the response rate of the combination
* Further evaluate the safety and side effect profile for the combination of TY-302 and Tamoxifen.
Study:
NCT04433494
Study Brief:
Protocol Section:
NCT04433494